Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as YL202 for injection; Toripalimab injection
YL202; Toripalimab · 1 trial · 3 indications
The purpose of DLT is to find maximum tolerated dose (MTD).
Nature and frequency of AEs with severity is aim to evaluate the safety of YL202 combination.
| Arm | Type | Description |
|---|---|---|
| YL202 in combination with Toripalimab | EXPERIMENTAL | Part 1 (dose escalation stage and backfill stage) \& Part 3 (dose expansion stage): YL202 for injection in combination with Toripalimab injection |
| YL202 in combination with Furmonertinib Mesilate | EXPERIMENTAL | Part 2 (dose escalation stage and backfill stage) \& Part 4 (dose expansion stage): YL202 for injection in combination with Furmonertinib Mesilate Tablets |
| Name | Type | Description |
|---|---|---|
| YL202 for injection; Toripalimab injection | DRUG | Part 1: YL202 and Toripalimab will be administered intravenously. Part 3: participants will receive escalating doses of YL202 and fixed dose of Toripalimab until YL202 doses for optimization are determined. Dose expansion stage: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Toripalimab |
| YL202 for injection; Furmonertinib Mesilate Tablets | DRUG | Part 2: YL202 will be administered intravenously，Furmonertinib Mesilate Tablets will be administered orally. Dose escalation stage: participants will receive escalating doses of YL202 and fixed dose of Furmonertinib Mesilate until YL202 doses for optimization are determined. Part 4: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Furmonertinib Mesilate. |
Inclusion Criteria: 1. Informed of the study before the start of the study and voluntarily sign their name and date in the informed consent form (ICF) 2. Able and willing to comply with protocol visits and procedures 3. Aged between 18 to 75 years 4. Eastern Cooperative Oncology Group performance s...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
YL202 is an investigational small molecule being studied for the treatment of advanced solid tumors, including breast cancer and non-small cell lung cancer. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
YL202 is a small molecule, but its specific molecular target has not been disclosed. The drug is being evaluated in combination with other anti-tumor therapies in patients with advanced solid tumors, and the clinical trial includes biomarker-selected patients.
YL202 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker YCBD. The company is conducting a Phase 1 clinical trial of YL202 in combination with other anti-tumor therapies for advanced solid tumors.
YL202 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is actively recruiting participants in China.
YL202 is being studied in a Phase 1 clinical trial with the identifier NCT07169994. This trial is evaluating YL202 in combination with other anti-tumor therapies in patients with advanced solid tumors, including breast cancer and non-small cell lung cancer, and is currently recruiting participants.
YL202 is also known as YL202 for injection and Toripalimab injection. The drug is referred to by these alternative names, and it is being developed by cbdMD, Inc. under the ticker YCBD.